Molecular basis of cholera blood-group dependence and implications for a world characterized by climate change

FEBS Letters

Volumn 584, Issue 12, 2010, Pages 2548-2555

  Holmner, Åsa ^a   Mackenzie, Alasdair ^b   Krengel, Ute ^b  

^a Vasterbotten County Council   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Blood group antigen recognition; Cholera toxin; Climate change global warming; Protein carbohydrate interaction; Structural biology; Vaccine development

Indexed keywords

ANTIBIOTIC AGENT; BLOOD GROUP ABH ANTIGEN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; GANGLIOSIDE GM1; N ACETYLGALACTOSAMINE; RAIN;

ANTIBIOTIC RESISTANCE; BLOOD GROUP; BLOOD GROUP O; CHOLERA; DISEASE SEVERITY; DRUG RESEARCH; ENVIRONMENTAL SANITATION; ENVIRONMENTAL TEMPERATURE; EPIDEMIOLOGICAL DATA; HUMAN; INFECTION PREVENTION; INFECTION SENSITIVITY; MOLECULAR MECHANICS; PRIORITY JOURNAL; REHYDRATION; REVIEW; SEA LEVEL; TREATMENT PLANNING; VIBRIO CHOLERAE; WATER CONTAMINATION;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP ANTIGENS; CHOLERA; CHOLERA TOXIN; CLIMATE CHANGE; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR;

EID: 77953129563     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.03.050     Document Type: Review

References (111)

1. Sack D.A., Sack R.B., Nair G.B., Siddique A.K. Cholera. Lancet 2004, 363:223-233.
2. Huq A., Small E.B., West P.A., Huq M.I., Rahman R., Colwell R.R. Ecological relationships between Vibrio cholerae and planktonic crustacean copepods. Appl. Environ. Microbiol. 1983, 45:275-283.
3. Tamplin M.L., Gauzens A.L., Huq A., Sack D.A., Colwell R.R. Attachment of Vibrio cholerae serogroup O1 to zooplankton and phytoplankton of Bangladesh waters. Appl. Environ. Microbiol. 1990, 56:1977-1980.
4. Shukla B.N., Singh D.V., Sanyal S.C. Attachment of non-culturable toxigenic Vibrio cholerae O1 and non-O1 and Aeromonas spp. to the aquatic arthropod Gerris spinolae and plants in the River Ganga, Varanasi. FEMS Immunol. Med. Microbiol. 1995, 12:113-120.
5. Abd H., Weintraub A., Sandström G. Intracellular survival and replication of Vibrio cholerae O139 in aquatic free-living amoebae. Environ. Microbiol. 2005, 7:1003-1008.
6. Alam M., Sultana M., Nair G.B., Siddique A.K., Hasan N.A., Sack R.B., Sack D.A., Ahmed K.U., Sadique A., Watanabe H., Grim C.J., Huq A., Colwell R.R. Viable but nonculturable Vibrio cholerae O1 in biofilms in the aquatic environment and their role in cholera transmission. Proc. Natl. Acad. Sci. USA 2007, 104:17801-17806.
7. Islam M.S., Jahid M.I.K., Rahman M.M., Rahman M.Z., Islam M.S., Kabir M.S., Sack D.A., Schoolnik G.K. Biofilm acts as a microenvironment for plankton-associated Vibrio cholerae in the aquatic environment of Bangladesh. Microbiol. Immunol. 2007, 51:369-379.
8. WHO (2010). http://www.who.int/topics/cholera/en/.
9. WHO (2009). Cholera in Zimbabwe - update 3. http://www.who.int/csr/don/2009_03_23/en/index.html.
10. Bhattacharya S., Black R., Bourgeois L., Clemens J., Cravioto A., Deen J.L., Dougan G., Glass R., Grais R.F., Greco M., Gust I., Holmgren J., Kariuki S., Lambert P.-H., Liu M.A., Longini I., Nair G.B., Norrby R., Nossal G.J.V., Ogra P., Sansonetti P., von Seidlein L., Songane F., Svennerholm A.-M., Steele D., Walker R. The cholera crisis in Africa. Science 2009, 324:885.
11. WHO (2003). Cholera unveiled... http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_ZFK_2003.3.pdf.
12. Sack D.A., Sack R.B., Chaignat C.-L. Getting serious about cholera. N. Engl. J. Med. 2006, 355:649-651.
13. Zuckerman J.N., Rombo L., Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infect. Dis. 2007, 7:521-530.
14. Davis B.M., Lawson E.H., Sandkvist M., Ali A., Sozhamannan S., Waldor M.K. Convergence of the secretory pathways for cholera toxin and the filamentous phage, CTXΦ. Science 2000, 288:333-335.
15. Davis B.M., Waldor M.K. Filamentous phages linked to virulence of Vibrio cholerae. Curr. Opin. Microbiol. 2003, 6:35-42.
16. Merritt E.A., Hol W.G.J. AB5 toxins. Curr. Opin. Struct. Biol. 1995, 5:165-171.
17. Chinnapen D.J.-F., Chinnapen H., Saslowsky D., Lencer W.I. Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol. Lett. 2007, 266:129-137.
18. De Haan L., Hirst T.R. Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms (Review). Mol. Membr. Biol. 2004, 21:77-92.
19. Nelson E.J., Harris J.B., Morris J.G., Calderwood S.B., Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat. Rev. Microbiol. 2009, 7:693-702.
20. WHO (2010). http://www.who.int/topics/cholera/vaccines/current/en/index.html.
21. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Stanton B.F., Kay B.A., Khan M.U., Yunus M., Atkinson W., Svennerholm A.-M., Holmgren J. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 328:124-127.
22. Lucas M.E., Deen J.L., von Seidlein L., Wang X.Y., Ampuero J., Puri M., Ali M., Ansaruzzaman M., Amos J., Macuamule A., Cavailler P., Guerin P.J., Mahoudeau C., Kahozi-Sangwa P., Chaignat C.L., Barreto A., Songane F.F., Clemens J.D. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med. 2005, 352:757-767.
23. Clemens J.D., Sack D.A., Harris J.R., van Loon F., Chakraborty J., Ahmed F., Rao M.R., Khan M.R., Yunus M., Huda N., Stanton B.F., Kay B.A., Walter S., Eeckels R., Svennerholm A.-M., Holmgren J. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
24. Ali M., Emch M., von Seidlein L., Yunus M., Sack D.A., Rao M., Holmgren J., Clemens J.D. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005, 366:44-49.
25. Longini I.M., Nizam A., Ali M., Yunus M., Shenvi N., Clemens J.D. Controlling endemic cholera with oral vaccines. PLoS Med. 2007, 4:e336.
26. Barua D., Paguio A.S. ABO blood groups and cholera. Ann. Hum. Biol. 1977, 4:489-492.
27. Chaudhuri A., De S. Cholera and blood-groups. Lancet 1977, 310:404.
28. Glass R.I., Holmgren J., Haley C.E., Khan M.R., Svennerholm A.-M., Stoll B.J., Hossain K.M.B., Black R.E., Yunus M., Barua D. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 1985, 121:791-796.
29. Swerdlow D.L., Mintz E.D., Rodriguez M., Tejada E., Ocampo C., Espejo L., Barrett T.J., Petzelt J., Bean N.H., Seminario L., Tauxe R.V. Severe life-threatening cholera associated with blood group O in Peru: implications for the Latin American epidemic. J. Infect. Dis. 1994, 170:468-472.
30. Faruque A.S.G., Mahalanabis D., Hoque S.S., Albert M.J. The relationship between ABO blood groups and susceptibility to diarrhea due to Vibrio cholerae 0139. Clin. Infect. Dis. 1994, 18:827-828.
31. Tacket C.O., Losonsky G., Nataro J.P., Wasserman S.S., Cryz S.J., Edelman R., Levine M.M. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans. R. Soc. Trop. Med. Hyg. 1995, 89:75-77.
32. Harris J.B., Khan A.I., LaRocque R.C., Dorer D.J., Chowdhury F., Faruque A.S.G., Sack D.A., Ryan E.T., Qadri F., Calderwood S.B. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect. Immun. 2005, 73:7422-7427.
33. Harris J.B., LaRocque R.C., Chowdhury F., Khan A.I., Logvinenko T., Faruque A.S.G., Ryan E.T., Qadri F., Calderwood S.B. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl. Trop. Dis. 2008, 2:e221.
34. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Huda S., Ahmed F., Gomes J., Rao M.R., Svennerholm A.-M., Holmgren J. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis. 1989, 159:770-773.
35. Berger S.A., Young N.A., Edberg S.C. Relationship between infectious diseases and human blood type. Eur. J. Clin. Microbiol. Infect. Dis. 1989, 8:681-689.
36. Hutson A.M., Atmar R.L., Graham D.Y., Estes M.K. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 2002, 185:1335-1337.
37. Malavige G.N., Ranatunga P.K., Velathanthiri V.G.N.S., Fernando S., Karunatilaka D.H., Aaskov J., Seneviratne S.L. Patterns of disease in Sri Lankan dengue patients. Arch. Dis. Child. 2006, 91:396-400.
38. Pathirana S.L., Alles H.K., Bandara S., Phone-Kyaw M., Perera M.K., Wickremasinghe A.R., Mendis K.N., Handunnetti S.M. ABO-blood-group types and protection against severe, Plasmodium falciparum malaria. Ann. Trop. Med. Parasitol. 2005, 99:119-124.
39. Uneke C.J. Plasmodium falciparum malaria and ABO blood group: is there any relationship?. Parasitol. Res. 2007, 100:759-765.
40. Rowe J.A., Handel I.G., Thera M.A., Deans A.-M., Lyke K.E., Koné A., Diallo D.A., Raza A., Kai O., Marsh K., Plowe C.V., Doumbo O.K., Moulds J.M. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc. Natl. Acad. Sci. USA 2007, 104:17471-17476.
41. Lund N., Olsson M.L., Ramkumar S., Sakac D., Yahalom V., Levene C., Hellberg Å., Ma X.-Z., Binnington B., Jung D., Lingwood C.A., Branch D.R. The human Pk histo-blood group antigen provides protection against HIV-1 infection. Blood 2009, 113:4980-4991.
42. Marionneau S., Cailleau-Thomas A., Rocher J., Le Moullac-Vaidye B., Ruvoën N., Clément M., Le Pendu J. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 2001, 83:565-573.
43. Seymour R.M., Allan M.J., Pomiankowski A., Gustafsson K. Evolution of the human ABO polymorphism by two complementary selective pressures. Proc. R. Soc. Lond. B 2004, 271:1065-1072.
44. Cserti C.M., Dzik W.H. The ABO blood group system and Plasmodium falciparum malaria. Blood 2007, 110:2250-2258.
45. Bishop J.R., Gagneux P. Evolution of carbohydrate antigens-microbial forces shaping host glycomes?. Glycobiology 2007, 17:23R-34R.
46. Imberty A., Varrot A. Microbial recognition of human cell surface glycoconjugates. Curr. Opin. Struct. Biol. 2008, 18:567-576.
47. Choi J.-M., Hutson A.M., Estes M.K., Prasad B.V.V. Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc. Natl. Acad. Sci. USA 2008, 105:9175-9180.
48. Cao S., Lou Z., Tan M., Chen Y., Liu Y., Zhang Z., Zhang X.C., Jiang X., Li X., Rao Z. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 2007, 81:5949-5957.
49. Bennun F.R., Roth G.A., Monferran C.G., Cumar F.A. Binding of cholera toxin to pig intestinal mucosa glycosphingolipids: relationship with the ABO blood group system. Infect. Immun. 1989, 57:969-974.
50. Monferran C.G., Roth G.A., Cumar F.A. Inhibition of cholera toxin binding to membrane receptors by pig gastric mucin-derived glycopeptides: differential effect depending on the ABO blood group antigenic determinants. Infect. Immun. 1990, 58:3966-3972.
51. Barra J.L., Monferran C.G., Balanzino L.E., Cumar F.A. Escherichia coli heat-labile enterotoxin preferentially interacts with blood group A-active glycolipids from pig intestinal mucosa and A- and B-active glycolipids from human red cells compared to H-active glycolipids. Mol. Cell. Biochem. 1992, 115:63-70.
52. Balanzino L.E., Barra J.L., Galván E.M., Roth G.A., Monferran C.G. Interaction of cholera toxin and Escherichia coli heat-labile enterotoxin with glycoconjugates from rabbit intestinal brush border membranes: relationship with ABH blood group determinants. Mol. Cell. Biochem. 1999, 194:53-62.
53. Balanzino L.E., Barra J.L., Monferran C.G., Cumar F.A. Differential interaction of Escherichia coli heat-labile toxin and cholera toxin with pig intestinal brush border glycoproteins depending on their ABH and related blood group antigenic determinants. Infect. Immun. 1994, 62:1460-1464.
54. Ångström J., Bäckström M., Berntsson A., Karlsson N., Holmgren J., Karlsson K.-A., Lebens M., Teneberg S. Novel carbohydrate binding site recognizing blood group A and B determinants in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits. J. Biol. Chem. 2000, 275:3231-3238.
55. Holmner Å., Lebens M., Teneberg S., Ångström J., Ökvist M., Krengel U. Novel binding site identified in a hybrid between cholera toxin and heat-labile enterotoxin: 1.9 Å crystal structure reveals the details. Structure 2004, 12:1655-1667.
56. Holmner Å., Askarieh G., Ökvist M., Krengel U. Blood group antigen recognition by Escherichia coli heat-labile enterotoxin. J. Mol. Biol. 2007, 371:754-764.
57. Mekalanos J.J., Swartz D.J., Pearson G.D.N., Harford N., Groyne F., de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 1983, 306:551-557.
58. Sánchez J., Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci. 2008, 65:1347-1360.
59. Loris R., Stas P.P.G., Wyns L. Conserved waters in legume lectin crystal structures. The importance of bound water for the sequence-structure relationship within the legume lectin family. J. Biol. Chem. 1994, 269:26722-26733.
60. Toone E.J. Structure and energetics of protein-carbohydrate complexes. Curr. Opin. Struct. Biol. 1994, 4:719-728.
61. Janin J. Wet and dry interfaces: the role of solvent in protein-protein and protein-DNA recognition. Structure 1999, 7:R277-R279.
62. Holmgren J., Lönnroth I., Månsson J.-E., Svennerholm L. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc. Natl. Acad. Sci. USA 1975, 72:2520-2524.
63. Finne J., Breimer M.E., Hansson G.C., Karlsson K.-A., Leffler H., Vliegenthart J.F.G., van Halbeek H. Novel polyfucosylated N-linked glycopeptides with blood group A, H, X, and Y determinants from human small intestinal epithelial cells. J. Biol. Chem. 1989, 264:5720-5735.
64. Breimer M.E. Tissue specificity of glycosphingolipids as expressed in pancreas and small intestine of blood group A and B human individuals. Arch. Biochem. Biophys. 1984, 228:71-85.
65. Björk S., Breimer M.E., Hansson G.C., Karlsson K.-A., Leffler H. Structures of blood group glycosphingolipids of human small intestine. A relation between the expression of fucolipids of epithelial cells and the ABO, Le and Se phenotype of the donor. J. Biol. Chem. 1987, 262:6758-6765.
66. Jansson L., Ångström J., Lebens M., Teneberg S. No direct binding of the heat-labile enterotoxin of Escherichia coli to E. coli lipopolysaccharides. Glycoconj. J. 2010, 27:171-179.
67. Chaudhuri A., DasAdhikary C.R. Possible role of blood-group secretory substances in the aetiology of cholera. Trans. R. Soc. Trop. Med. Hyg. 1978, 72:664-665.
68. Perrier C., Sprenger N., Corthésy B. Glycans on secretory component participate in innate protection against mucosal pathogens. J. Biol. Chem. 2006, 281:14280-14287.
69. Moncada D.M., Kammanadiminti S.J., Chadee K. Mucin and Toll-like receptors in host defense against intestinal parasites. Trends Parasitol. 2003, 19:305-311.
70. Galván E.M., Roth G.A., Monferran C.G. Functional interaction of Escherichia coli heat-labile enterotoxin with blood group A-active glycoconjugates from differentiated HT29 cells. FEBS J. 2006, 273:3444-3453.
71. Guidry J.J., Cárdenas L., Cheng E., Clements J.D. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect. Immun. 1997, 65:4943-4950.
72. Jobling M.G., Holmes R.K. Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol. Microbiol. 1991, 5:1755-1767.
73. IPCC (2007). Impacts, Adaption and Vulnerability, In IPCC report (Climate Change 2007: Working Group II) http://www.ipcc.ch/ipccreports/ar4-wg2.htm.
74. Bender M.A., Knutson T.R., Tuleya R.E., Sirutis J.J., Vecchi G.A., Garner S.T., Held I.M. Modeled impact of anthropogenic warming on the frequency of intense Atlantic hurricanes. Science 2010, 327:454-458.
75. Thomas M.K., Charron D.F., Waltner-Toews D., Schuster C., Maarouf A.R., Holt J.D. A role of high impact weather events in waterborne disease outbreaks in Canada, 1975-2001. Int. J. Environ. Health. Res. 2006, 16:167-180.
76. Signor R.S., Ashbolt N.J., Roser D.J. Microbial risk implications of rainfall-induced runoff events entering a reservoir used as a drinking-water source. Journal of Water Supply: Research and Technology - AQUA 2007, 56:515-531.
77. Richardson H.Y., Nichols G., Lane C., Lake I.R., Hunter P.R. Microbiological surveillance of private water supplies in England - The impact of environmental and climate factors on water quality. Water Res. 2009, 43:2159-2168.
78. Colwell R.R. Global climate and infectious disease: the cholera paradigm. Science 1996, 274:2025-2031.
79. Pascual M., Rodó X., Ellner S.P., Colwell R., Bouma M.J. Cholera dynamics and El Niño-Southern Oscillation. Science 2000, 289:1766-1769.
80. Pascual M., Bouma M.J., Dobson A.P. Cholera and climate: revisiting the quantitative evidence. Microbes Infect. 2002, 4:237-245.
81. Huq A., Sack R.B., Nizam A., Longini I.M., Nair G.B., Ali A., Morris J.G., Khan M.N.H., Siddique A.K., Yunus M., Albert M.J., Sack D.A., Colwell R.R. Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh. Appl. Environ. Microbiol. 2005, 71:4645-4654.
82. Fernández M.A.L., Bauernfeind A., Jiménez J.D., Gil C.L., El Omeiri N., Guibert D.H. Influence of temperature and rainfall on the evolution of cholera epidemics in Lusaka, Zambia, 2003-2006: analysis of a time series. Trans. R. Soc. Trop. Med. Hyg. 2009, 103:137-143.
83. Islam M.S., Sharker M.A.Y., Rheman S., Hossain S., Mahmud Z.H., Uddin A.M.K., Islam M.S., Yunus M., Osman M.S., Ernst R., Rector I., Larson C.P., Luby S.P., Endtz H.P., Cravioto A. Effects of local climate variability on transmission dynamics of cholera in Matlab, Bangladesh. Trans. R. Soc. Trop. Med. Hyg. 2009, 103:1165-1170.
84. Franco A.A., Fix A.D., Prada A., Paredes E., Palomino J.C., Wright A.C., Johnson J.A., McCarter R., Guerra H., Morris J.G. Cholera in Lima, Peru, correlates with prior isolation of Vibrio cholerae from the environment. Am. J. Epidemiol. 1997, 146:1067-1075.
85. Koelle K., Rodó X., Pascual M., Yunus M., Mostafa G. Refractory periods and climate forcing in cholera dynamics. Nature 2005, 436:696-700.
86. Cash R.A., Music S.I., Libonati J.P., Craig J.P., Pierce N.F., Hornick R.B. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J. Infect. Dis. 1974, 130:325-333.
87. Levine M.M., Nalin D.R., Craig J.P., Hoover D., Bergquist E.J., Waterman D., Holley H.P., Hornick R.B., Pierce N.P., Libonati J.P. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg. 1979, 73:3-9.
88. Glass R.I., Becker S., Huq M.I., Stoll B.J., Khan M.U., Merson M.H., Lee J.V., Black R.E. Endemic cholera in rural Bangladesh, 1966-1980. Am. J. Epidemiol. 1982, 116:959-970.
89. Mourant A.E., Kopeć A.C., Domaniewska-Sobczak K. The distribution of the human blood groups and other polymorphisms 1976, Oxford University Press. 2nd ed.
90. Vu D.T., Hossain M.M., Nguyen D.S., Nguyen T.H., Rao M.R., Do G.C., Naficy A., Nguyen T.K., Acosta C.J., Deen J.L., Clemens J.D., Dang D.T. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J. Health. Popul. Nutr. 2003, 21:304-308.
91. Lopez A.L., Clemens J.D., Deen J., Jodar L. Cholera vaccines for the developing world. Hum. Vaccine 2008, 4:165-169.
92. Drazen J.M., Klempner M.S. Disaster, water, cholera, vaccines, and hope. N. Engl. J. Med. 2005, 352:827.
93. Merrell D.S., Butler S.M., Qadri F., Dolganov N.A., Alam A., Cohen M.B., Calderwood S.B., Schoolnik G.K., Camilli A. Host-induced epidemic spread of the cholera bacterium. Nature 2002, 417:642-645.
94. Hartley D.M., Morris J.G., Smith D.L. Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics?. PLoS Med. 2006, 3:e7.
95. Clemens J.D., Harris J.R., Sack D.A., Chakraborty J., Ahmed F., Stanton B.F., Khan M.U., Kay B.A., Huda N., Khan M.R., Yunus M., Rao M.R., Svennerholm A.-M., Holmgren J. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 1988, 158:60-69.
96. Rask C., Fredriksson M., Lindblad M., Czerkinsky C., Holmgren J. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant. APMIS 2000, 108:178-186.
97. De Haan L., Verweij W., Agsteribbe E., Wilschut J. The role of ADP-ribosylation and GM1-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. Immunol. Cell. Biol. 1998, 76:270-279.
98. Lycke N. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 1997, 148:504-520.
99. Connell T.D. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev. Vaccines 2007, 6:821-834.
100. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., Huda N., Khan M.U., Kay B.A., Khan M.R., Ansaruzzaman M., Yunus M., Rao M.R., Svennerholm A.-M., Holmgren J. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 1988, 158:372-377.
101. Peltola H., Siitonen A., Kyrönseppä H., Simula I., Mattila L., Oksanen P., Kataja M.J., Cadoz M. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338:1285-1289.
102. Lebens M., Shahabi V., Bäckström M., Houze T., Lindblad M., Holmgren J. Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine. Infect. Immun. 1996, 64:2144-2150.
103. Mwansa J.C.L., Mwaba J., Lukwesa C., Bhuiyan N.A., Ansaruzzaman M., Ramamurthy T., Alam M., Nair G.B. Multiply antibiotic-resistant Vibrio cholerae O1 biotype El Tor strains emerge during cholera outbreaks in Zambia. Epidemiol. Infect. 2007, 135:847-853.
104. Cheshev P., Morelli L., Marchesi M., Podlipnik Č., Bergström M., Bernardi A. Synthesis and affinity evaluation of a small library of bidentate cholera toxin ligands: towards nonhydrolyzable ganglioside mimics. Chem. Eur. J. 2010, 16:1951-1967.
105. Pukin A.V., Branderhorst H.M., Sisu C., Weijers C.A.G.M., Gilbert M., Liskamp R.M.J., Visser G.M., Zuilhof H., Pieters R.J. Strong inhibition of cholera toxin by multivalent GM1 derivatives. ChemBioChem 2007, 8:1500-1503.
106. Branderhorst H.M., Liskamp R.M.J., Visser G.M., Pieters R.J. Strong inhibition of cholera toxin binding by galactose dendrimers. Chem. Commun. 2007, 47:5043-5045.
107. Liu J., Begley D., Mitchell D.D., Verlinde C.L.M.J., Varani G., Fan E. Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand interactions. Chem. Biol. Drug Des. 2008, 71:408-419.
108. Sisu C., Baron A.J., Branderhorst H.M., Connell S.D., Weijers C.A.G.M., de Vries R., Hayes E.D., Pukin A.V., Gilbert M., Pieters R.J., Zuilhof H., Visser G.M., Turnbull W.B. The influence of ligand valency on aggregation mechanisms for inhibiting bacterial toxins. ChemBioChem 2009, 10:329-337.
109. O'Neal C.J., Amaya E.I., Jobling M.G., Holmes R.K., Hol W.G.J. Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry 2004, 43:3772-3782.
110. Merritt E.A., Kuhn P., Sarfaty S., Erbe J.L., Holmes R.K., Hol W.G.J. The 1.25 Å resolution refinement of the cholera toxin B-pentamer: evidence of peptide backbone strain at the receptor-binding site. J. Mol. Biol. 1998, 282:1043-1059.
111. DeLano, W.L. .